Table of Contents
Leukemia Research and Treatment
Volume 2015 (2015), Article ID 489592, 6 pages
http://dx.doi.org/10.1155/2015/489592
Research Article

Isochromosome 17q in Chronic Lymphocytic Leukemia

1Jena University Hospital, Friedrich Schiller University, Institute of Human Genetics, Kollegiengasse 10, 07743 Jena, Germany
2Croatian Institute of Brain Research, Salata 12, 1000 Zagreb, Croatia
3Laboratory of Cytogenetics and Genomics, Faculty of Medicine, University of Coimbra, Polo Ciências da Saúde, 3000-548 Coimbra, Portugal
4Centro de Investigação em Meio Ambiente, Genética e Oncobiologia (CIMAGO), Polo Ciências da Saúde, 3000-548 Coimbra, Portugal

Received 25 August 2015; Revised 21 October 2015; Accepted 17 November 2015

Academic Editor: Antonio Cuneo

Copyright © 2015 Eyad Alhourani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

In chronic lymphocytic leukemia (CLL), presence of acquired cytogenetic abnormalities may help to estimate prognosis. However, deletion of TP53 gene, which is associated with an aggressive course of the disease and poor prognosis along with a lack of response to treatment, is one of the alterations which may escape cytogenetic diagnoses in CLL. Thus, other techniques have emerged such as interphase fluorescence in situ hybridization (iFISH). Deletion of TP53 may but must not go together with the formation of an isochromosome i(17q); surprisingly this subgroup of patients was not in the focus of CLL studies yet. This study was about if presence of i(17q) could be indicative for a new subgroup in CLL with more adverse prognosis. As a result, TP53 deletion was detected in 18 out of 150 (12%) here studied CLL cases. Six of those cases (~33%) had the TP53 deletion accompanied by an i(17q). Interestingly, the cases with i(17q) showed a tendency towards more associated chromosomal aberrations. These findings may be the bases for follow-up studies in CLL patients with TP53 deletion with and without i(17q); it may be suggested that the i(17q) presents an even more adverse prognostic marker than TP53 deletion alone.